Literature DB >> 18598596

The use of warfarin as thromboprophylaxis for lower limb arthroplasty.

Mark R Dunbar1, Piyush K Upadhyay, Shanmugam Karthikeyan.   

Abstract

INTRODUCTION: Most orthopaedic surgeons in the UK use some form of prophylaxis against venous thromboembolic events. Warfarin has been recommended as one of the preferred methods to use. The period of in-hospital postoperative rehabilitation has reduced significantly since lower limb arthroplasty was introduced. We sought to identify and quantify any delay in discharge associated in using warfarin as chemical prophylaxis. PATIENTS AND METHODS: During a 12-week period, all patients undergoing a lower limb arthroplasty procedure were identified and any delay in discharge related to their warfarin prophylaxis was recorded.
RESULTS: Of the 25 arthroplasties performed in this time period, 17 (68%) were subject to a delay. The total delay in discharge was 39 days. When the standard warfarin dosing protocol was followed, 33% of patients were still delayed. When the protocol was not followed, only 23% were delayed. The majority of deviations from the protocol led to a shorter hospital stay. DISCUSSION: Patients using warfarin prophylaxis generate an additional cost of 417 pounds related to bed occupancy. There is considerable scope for significantly reducing this cost by moving the early postoperative anticoagulation monitoring into the community. Delayed discharge is an important consideration in the economic issues that surround the choice of thromboprophylaxis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18598596      PMCID: PMC2647245          DOI: 10.1308/003588408X300957

Source DB:  PubMed          Journal:  Ann R Coll Surg Engl        ISSN: 0035-8843            Impact factor:   1.891


  9 in total

Review 1.  Thromboprophylaxis in patients undergoing total hip replacement.

Authors:  I J Brenkel; R E Cook
Journal:  Hosp Med       Date:  2003-05

Review 2.  Risk of and prophylaxis for venous thromboembolism in hospital patients. Thromboembolic Risk Factors (THRIFT) Consensus Group.

Authors: 
Journal:  BMJ       Date:  1992-09-05

3.  Direct costs of warfarin treatment among patients with atrial fibrillation in a Finnish health care setting.

Authors:  T Hallinen; J A Martikainen; E J O Soini; L Suominen; T Aronkytö
Journal:  Curr Med Res Opin       Date:  2006-04       Impact factor: 2.580

4.  Warfarin prophylaxis to prevent mortality from pulmonary embolism after total hip replacement.

Authors:  H C Amstutz; D A Friscia; F Dorey; B T Carney
Journal:  J Bone Joint Surg Am       Date:  1989-03       Impact factor: 5.284

Review 5.  Cost effectiveness of the prevention and treatment of deep vein thrombosis and pulmonary embolism.

Authors:  D R Anderson; B J O'Brien
Journal:  Pharmacoeconomics       Date:  1997-07       Impact factor: 4.981

6.  Quality of anticoagulation control and costs of monitoring warfarin therapy among patients with atrial fibrillation in clinic settings: a multi-site managed-care study.

Authors:  Joseph Menzin; Luke Boulanger; Ole Hauch; Mark Friedman; Cheryl Beadle Marple; Gail Wygant; Judith S Hurley; Stephen Pezzella; Scott Kaatz
Journal:  Ann Pharmacother       Date:  2005-02-08       Impact factor: 3.154

7.  Thromboprophylaxis and death after total hip replacement.

Authors:  D W Murray; A R Britton; C J Bulstrode
Journal:  J Bone Joint Surg Br       Date:  1996-11

Review 8.  Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.

Authors:  William H Geerts; Graham F Pineo; John A Heit; David Bergqvist; Michael R Lassen; Clifford W Colwell; Joel G Ray
Journal:  Chest       Date:  2004-09       Impact factor: 9.410

9.  Minimal incision total knee arthroplasty: early experience.

Authors:  Alfred J Tria; Thomas M Coon
Journal:  Clin Orthop Relat Res       Date:  2003-11       Impact factor: 4.176

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.